The Induced Expression of Immune-related Molecules Stimulated by Toll-like Receptor 7 Agonist Gardiquimod in Peripheral Blood Monouclear Cells Isolated from Renal Cancer Patients_West China Medical Journal

Authors：

 CHENLiang , WUBo

Surgical Department Ⅱ, Pixian County People's Hospital, Pixian, Sichuan 611730, P. R. China;

Corresponding author：

Keywords：

Renal cancer; Toll-like receptor 7; Gardiquimod; Immune-related molecules

DOI：

10.7507/1002-0179.20150580

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the expression variation of immune-related molecules in perpheral blood monouclear cells (PBMC) from renal cancer patient upon Toll-like receptor 7 (TLR7) agonist Gardiquimod stimulation. Methods The study was carried out in June 2013 on one patient with renal cancer. PBMC isolated from the patient were stimulated by Gardiquimod and real-time polymerase chain reaction was conducted to measure the expression variation of many immune-related molecules. Results Among all molecules influenced by TLR7 agonist, adhesion molecules were down-regulated by Gardiquimod, while the majority members of cytokines, chemokines and interleukins were dramatically induced in the presence of Gardiquimod. Conclusion TLR7 pathway plays an important role in regulating the immune responses and can be used as potential target in renal cancer.

Citation： CHENLiang, WUBo. The Induced Expression of Immune-related Molecules Stimulated by Toll-like Receptor 7 Agonist Gardiquimod in Peripheral Blood Monouclear Cells Isolated from Renal Cancer Patients. West China Medical Journal, 2015, 30(11): 2035-2039. doi: 10.7507/1002-0179.20150580 Copy

1.	Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer:large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method[J]. Cancer, 2012, 118(18):4427-4436.
2.	Nepple KG, Yang L, Grubb RL, et al. Population based analysis of the increasing incidence of kidney cancer in the United States:evaluation of age specific trends from 1975 to 2006[J]. J Urol, 2012, 187(1):32-38.
3.	Cohen HT, Mcgovern FJ. Renal-cell carcinoma[J]. N Eng J Med, 2005, 13(2):2477-2490.
4.	仉洁, 钟理, 石伟, 等. 肾细胞癌免疫治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2013, 20(1):120-123.
5.	Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors[J]. Semin Immunol, 2007, 19(1):3-10.
6.	Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors[J]. Curr Opin Immunol, 2003, 15 (4):396-401.
7.	Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy[J]. Oncogene, 2008, 27(2):190-199.
8.	Ghosh TK, Mickelson DJ, Solberg JC, et al. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha[J]. Int Immunopharmacol, 2007, 7(8):1111-1121.
9.	马建辉. 晚期肾癌靶向治疗临床研究现状[J]. 实用肿瘤杂志, 2010, 25(3):257-260.
10.	张永贞, 杨国庆, 王新正, 等. 2003～2007年中国肾及泌尿系统其他癌发病分析[J]. 中国肿瘤, 2012, 21(8):561-565.
11.	那彦群, 叶章群, 孙颖浩, 等. 中国泌尿外科疾病诊断治疗指南[M]. 北京:人民卫生出版社, 2013.
12.	Delahunt B, Eble JN, Mccredie MR, et al. Morphologic typing of papillary renal cell carcinoma:comparison of growth kinetics and patient survival in 66 cases[J]. Hum Pathol, 2001, 32(6):590-595.
13.	Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy:the many faces of renal cell carcinoma[J]. Rev Urol, 2002, 4(4):163-170.
14.	张卫民, 何廉波. 肾癌治疗的研究进展[J]. 河北医学, 2009, 15(9):1122-1123.
15.	Rosenberg SA. Gene therapy for cancer[J]. JAMA, 1992, 268(17):2416-2419.
16.	Shiba M, Nonomura N, Nakai Y, et al. Type-Ⅰinterferon receptor expression:its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients[J]. Int J Urol, 2009, 16(4):356-359.
17.	Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell[J]. J Exp Med, 1972, 136(1):128-142.
18.	Montagna D, Turin I, Schiavo R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor[J]. Cytotherapy, 2012, 14(1):80-90.
19.	Dillman RO. Cancer immunotherapy[J]. Cancer Biother Radiopharm, 2011, 26(1):1-64.
20.	Galanis E, Burch PA, Richardson RL, et al. Intratumoral administration of a 1, 2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/ dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma[J]. Cancer, 2004, 101(11):2557-2566.
21.	孙飞达, 王东文, 米振国. 肾癌分子靶向治疗的现状及研究进展[J]. 现代泌尿生殖肿瘤杂志, 2012, 4(1):1-3.
22.	Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J]. Nat Immunol, 2010, 11(5):373-384.
23.	Kaisho T, Akira S. Toll-like receptor function and signaling[J]. J Allergy Clin Immunol, 2006, 117(5):979-987; quiz 988.
24.	Smits EL, Cools N, Lion E, et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells[J]. Cancer Immunol Immunother, 2010, 59(1):35-46.

1. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer:large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method[J]. Cancer, 2012, 118(18):4427-4436.
2. Nepple KG, Yang L, Grubb RL, et al. Population based analysis of the increasing incidence of kidney cancer in the United States:evaluation of age specific trends from 1975 to 2006[J]. J Urol, 2012, 187(1):32-38.
3. Cohen HT, Mcgovern FJ. Renal-cell carcinoma[J]. N Eng J Med, 2005, 13(2):2477-2490.
4. 仉洁, 钟理, 石伟, 等. 肾细胞癌免疫治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2013, 20(1):120-123.
5. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors[J]. Semin Immunol, 2007, 19(1):3-10.
6. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors[J]. Curr Opin Immunol, 2003, 15 (4):396-401.
7. Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy[J]. Oncogene, 2008, 27(2):190-199.
8. Ghosh TK, Mickelson DJ, Solberg JC, et al. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha[J]. Int Immunopharmacol, 2007, 7(8):1111-1121.
9. 马建辉. 晚期肾癌靶向治疗临床研究现状[J]. 实用肿瘤杂志, 2010, 25(3):257-260.
10. 张永贞, 杨国庆, 王新正, 等. 2003～2007年中国肾及泌尿系统其他癌发病分析[J]. 中国肿瘤, 2012, 21(8):561-565.
11. 那彦群, 叶章群, 孙颖浩, 等. 中国泌尿外科疾病诊断治疗指南[M]. 北京:人民卫生出版社, 2013.
12. Delahunt B, Eble JN, Mccredie MR, et al. Morphologic typing of papillary renal cell carcinoma:comparison of growth kinetics and patient survival in 66 cases[J]. Hum Pathol, 2001, 32(6):590-595.
13. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy:the many faces of renal cell carcinoma[J]. Rev Urol, 2002, 4(4):163-170.
14. 张卫民, 何廉波. 肾癌治疗的研究进展[J]. 河北医学, 2009, 15(9):1122-1123.
15. Rosenberg SA. Gene therapy for cancer[J]. JAMA, 1992, 268(17):2416-2419.
16. Shiba M, Nonomura N, Nakai Y, et al. Type-Ⅰinterferon receptor expression:its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients[J]. Int J Urol, 2009, 16(4):356-359.
17. Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell[J]. J Exp Med, 1972, 136(1):128-142.
18. Montagna D, Turin I, Schiavo R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor[J]. Cytotherapy, 2012, 14(1):80-90.
19. Dillman RO. Cancer immunotherapy[J]. Cancer Biother Radiopharm, 2011, 26(1):1-64.
20. Galanis E, Burch PA, Richardson RL, et al. Intratumoral administration of a 1, 2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/ dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma[J]. Cancer, 2004, 101(11):2557-2566.
21. 孙飞达, 王东文, 米振国. 肾癌分子靶向治疗的现状及研究进展[J]. 现代泌尿生殖肿瘤杂志, 2012, 4(1):1-3.
22. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J]. Nat Immunol, 2010, 11(5):373-384.
23. Kaisho T, Akira S. Toll-like receptor function and signaling[J]. J Allergy Clin Immunol, 2006, 117(5):979-987; quiz 988.
24. Smits EL, Cools N, Lion E, et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells[J]. Cancer Immunol Immunother, 2010, 59(1):35-46.

West China Medical Journal

The Induced Expression of Immune-related Molecules Stimulated by Toll-like Receptor 7 Agonist Gardiquimod in Peripheral Blood Monouclear Cells Isolated from Renal Cancer Patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content